FDA accelerates review of Novartis’ sickle cell drugThe FDA has accelerated its review of Novartis’ sickle cell drug crizanlizumab after the company filed phase 2 Share XFDA accelerates review of Novartis’ sickle cell drughttps://pharmaphorum.com/news/fda-accelerates-review-of-novartis-sickle-cell-drug/
Novartis’ sickle cell drug gets Breakthrough Therapy designationThe FDA has granted Breakthrough Therapy designation to Novartis’ crizanlizumab for the prevention of vaso-occlusive crises (VOCs) in Share XNovartis’ sickle cell drug gets Breakthrough Therapy designationhttps://pharmaphorum.com/news/novartis-sickle-cell-drug-gets-breakthrough-therapy-designation/
GBT heads to FDA with sickle cell drug voxelotorGlobal Blood Therapeutics (GBT) has persuaded the FDA to accept biomarker data from a phase III trial of Share XGBT heads to FDA with sickle cell drug voxelotorhttps://pharmaphorum.com/news/gbt-heads-to-fda-with-sickle-cell-drug-voxelotor/
Novartis drug cuts serious complications in sickle cell diseaseNovartis’ developmental sickle cell disease drug crizanlizumab cut occurrences of a serious complication of the disease that can Share XNovartis drug cuts serious complications in sickle cell diseasehttps://pharmaphorum.com/news/novartis-drug-cuts-serious-complications-in-sickle-cell-disease/
Novartis buys sickle cell biotech SelexysSwiss pharma takes option on US biotech. Share XNovartis buys sickle cell biotech Selexyshttps://pharmaphorum.com/news/novartis-buys-us-biotech-selexys/
